Potential limited cross-drug reaction among fluoroquinolones: A large database analysis by International Classification of Diseases, Tenth Revision code-based approach
Abstract
Background: Fluoroquinolone allergy is the third most commonly reported antibiotic allergy. Cross-drug reactions among fluoroquinolones remain a clinical concern, although existing studies are limited by small sample sizes and a lack of control groups.
Objective: We aimed to assess the real-world frequency and risk of potential fluoroquinolone cross-drug reactions using a large health care database.
Methods: We performed a retrospective analysis using the TriNetX database in September 2025. Patients with an allergy label to ciprofloxacin, levofloxacin, or moxifloxacin who were subsequently exposed to a different fluoroquinolone were identified. Potential cross-drug reactions following the second fluoroquinolone exposure were assessed based on the International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes. Odds ratios for potential cross-drug reactions were calculated.
Results: The frequencies of potential cross-drug reactions following a second fluoroquinolone exposure were as follows: 2.6% (index allergy to ciprofloxacin, subsequent allergy to levofloxacin), 1.5% (ciprofloxacin → moxifloxacin), 2.7% (levofloxacin → ciprofloxacin), 1.3% (levofloxacin → moxifloxacin), 2.9% (moxifloxacin → ciprofloxacin), and 2.9% (moxifloxacin → levofloxacin). Compared with patients without an index fluoroquinolone allergy, the odds of experiencing a potential cross-drug reaction were slightly higher in some drug pairs: 1.18 (ciprofloxacin → levofloxacin;…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.